An official website of the United States government
These are Cohort Consortium-approved projects that have been completed or closed and are therefore no longer active. For more information please contact the investigator(s).
A pooled investigation of circulating adiponectin and multiple myeloma
Primary Investigator:
Mark PurdueProject Details:
View more information here.Related Publications:
Circulating resistin levels and risk of multiple myeloma in three prospective cohorts. (2017)
African American Working Group
Investigator(s):
Julie R. Palmer (jpalmer@bu.edu), William J. Blot (william.j.blot@Vanderbilt.Edu), Nonye Harvey (harveyn@mail.nih.gov), and othersYear Initiated:
2011Project Background:
The African American Working Group of the NCI Cohort Consortium was formed in 2011 when seven large epidemiology cohorts, each with at least 10,000 African American participants, joined to look at anthropometric measures in relation to mortality in African Americans. The original goals of the Working Group were to assess the relation of body mass index to all-cause, cancer, and CVD mortality, and then pancreas cancer and multiple myeloma, in African American men and women. Limited NCI extramural funds supported data harmonization and preparation of analysis datasets. Since then the Working Group's objectives have expanded to broadly examine determinants of cancer risk and outcome among African Americans. The group now provides a platform for development of new collaborative research leveraging existing data and resources in the Cohort Consortium. The seven cohorts participating in this project are: NIH-AARP; Adventist Health Study 2; Black Women's Health Study; Cancer Prevention Study II; Multiethnic Cohort Study; Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial; and Southern Community Cohort StudyRelated Publications:
Multiple Myeloma Mortality in Relation to Obesity Among African Americans. (2016)
A pooled analysis of body mass index and pancreatic cancer mortality in african americans. (2014)
A pooled analysis of body mass index and mortality among African Americans. (2014)
Aspirin, non-aspirin NSAID, acetaminophen use and ovarian cancer risk
Primary Investigator:
Britton TrabertProject Details:
View more information here.Related Publications:
Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. (2019)
BMI and Mortality in Asian Americans
Investigator(s):
Yikyung Park (yikyung.park@nih.gov), Sophia Wang (sowang@coh.org), Walter Willett (walter.willett@channing.harvard.edu), and othersYear Initiated:
2011Project Background:
This project evaluated the association between BMI and mortality in 20,672 Asian Americans by pooling data from 10 prospective cohort studies. Results were published in 2014.BMI and Multiple Myeloma Mortality
Investigator(s):
Lauren Teras (lauren.teras@cancer.org), Cari Kitahara (kitaharac@mail.nih.gov), Mark Purdue (purduem@mail.nih.gov), and othersYear Initiated:
2012Project Background:
This project evaluated the relationship between anthropometric measures (e.g., height, baseline BMI, young-adult BMI, BMI change, waist/hip ratio) and death from multiple myeloma by pooling data from 20 prospective cohort studies, including 1.5 million study participants. Results were published in 2014.Related Publications:
Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. (2014)
BMI, Body Fat Distribution, and Mortality
Investigator(s):
James Cerhan (cerhan.james@mayo.edu), Patricia Hartge (hartgep@mail.nih.gov), Leslie Bernstein (lbernstein@coh.org), and Amy Berrington de Gonzalez (berringtona@mail.nih.gov) for the BMI Cohort ConsortiumYear Initiated:
2011Project Background:
This project began in 2011 to assess the association of waist circumference with total and selected cause-specific (e.g., cardiovascular, cancer) mortality. A secondary analysis assessed hip circumference and waist-to-hip ratio, using data on more than 650,000 participants from 11 cohorts in the BMI and Mortality and Physical Activity Pooling Projects. The project has been completed and a manuscript is being submitted to a peer reviewed journal.Related Publications:
A pooled analysis of waist circumference and mortality in 650,000 adults. (2014)
Biomarkers and Breast Cancer Risk Prediction in Younger Women
Investigator(s):
Anne Zeleniuch-Jacquotte (anne.jacquotte@nyumc.org)Year Initiated:
2012Project Background:
This study, initiated in 2012, is developing an improved breast cancer risk prediction model for premenopausal women under 50 years of age. The model could have applications for both screening and chemoprevention. The study is assessing whether adding biomarkers (i.e., testosterone, free testosterone, circulating Müllerian Inhibiting Substance [MIS]) to the Breast Cancer Risk Assessment Tool (also known as the Gail Model) improves risk prediction in women under 50. The results could help younger women decide: (1) the most appropriate age to begin screening, and (2) whether to take tamoxifen for chemoprevention.Related Documents:
- Biomarkers and Breast Cancer Risk Prediction in Young Women Working Group_Zeleniuch-Jacquotte_9 25 2015.docx [DOCX - 23.4 KB]
- Zeleniuch- Biomarkers BrCa YW_2012.pdf [PDF - 547.6 KB]
- Biomarkers and Breast Cancer Risk Prediction in Younger Women.docx [DOCX - 13.4 KB]
- Biomarkers and Breast Cancer Risk Prediction in Younger Women.pdf [PDF - 321.1 KB]
Related Publications:
Body Mass Index (BMI) All-Cause Mortality Pooling Project
Investigator(s):
Amy Berrington de Gonzalez (berringtona@mail.nih.gov), Michael Thun (michael.thun@cancer.org), and othersYear Initiated:
2007Project Background:
This project began in 2007 as a collaborative effort among more than 20 prospective epidemiologic studies to examine and quantify the relationship between BMI and all-cause mortality; and determine the extent to which the relationship between BMI and all-cause mortality varies by factors such as age, sex, smoking status, preexisting heart disease or cancer, physical activity, alcohol intake, education, and marital status. The project analyzed pooled data from prospective studies encompassing 1.46 million adults to estimate hazard ratios for the association between BMI and all-cause mortality. The results were published in 2010. For more information, please visit: https://epi.grants.cancer.gov/bmi-pooling-project/Related Publications:
Body mass index and risk of death in Asian Americans. (2014)
Body-mass index and mortality among 1.46 million white adults. (2010)
Breast and Prostate Cancer Cohort Consortium (BPC3) (Phase I)
Investigator(s):
David Hunter (david.hunter@channing.harvard.edu), Michael Thun (michael.thun@cancer.org), Elio Riboli (e.riboli@imperial.ac.uk), and Brian HendersonYear Initiated:
2003Project Background:
The BPC3 began in 2003 to study hormone-related gene variants and environmental factors involved in the development of breast and prostate cancers. The goal was to characterize variations in about 55 candidate genes that mediate the steroid hormone metabolism and insulin-like growth factor (IGF) signaling pathways, and associate these variations with cancer risk. In 2007, the BPC3 expanded the study population and used a genome-wide association approach to identify genetic variants that may be associated with estrogen receptor negative breast cancer, as well as aggressive forms of prostate cancer. For more information, please visit: https://epi.grants.cancer.gov/bpc3/Related Publications:
Association of breast cancer risk loci with breast cancer survival. (2015)
Genome-wide association study of prostate cancer-specific survival. (2015)
Genetic risk variants associated with in situ breast cancer. (2015)
A genome-wide pleiotropy scan for prostate cancer risk. (2015)
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. (2013)
Genome-wide association study identifies new prostate cancer susceptibility loci. (2011)
Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. (2010)
Performance of common genetic variants in breast-cancer risk models. (2010)
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. (2009)
Complex diseases, complex genes: keeping pathways on the right track. (2009)
Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. (2008)
Multiple loci identified in a genome-wide association study of prostate cancer. (2008)
Haplotypes of the estrogen receptor beta gene and breast cancer risk. (2008)
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. (2007)
A common 8q24 variant in prostate and breast cancer from a large nested case-control study. (2007)
Exploiting gene-environment interaction to detect genetic associations. (2007)
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. (2005)
Genetic variation in the HSD17B1 gene and risk of prostate cancer. (2005)
Breast and Prostate Cancer Cohort Consortium (BPC3) (Phase II)
Investigator(s):
Susan Gapstur (susan.gapstur@cancer.org), Stephen Chanock (chanocks@mail.nih.gov), Mia Gaudet (mia.gaudet@cancer.org), Peter Kraft (pkraft@hsph.harvard.edu) and othersYear Initiated:
2007Project Background:
This new BPC3 study will expand the first phase of BPC3 to serve as a rapid verification test set for SNPs identified in the scans other than the CGEMS scan, and to examine gene-environment interactions in the SNPs identified in CGEMS and other studies as being associated with breast and prostate cancer. With the completion of GWAS for breast cancer and prostate cancers in aggregate, important questions remain that the BPC3 is uniquely positioned to answer. Estrogen receptor negative (ER-) breast cancers have specific epidemiologic characteristics and greater lethality, but the current generation of scans is underpowered to discover gene variants associated with these tumors. Aggressive forms of prostate cancer, characterized by extraprostatic extension (Stage C/D) or high histologic grade (Gleason score 8+), differ epidemiologically from the vastly more common indolent forms of prostate cancer and are of the greatest clinical importance, but again the current scans are underpowered to discover associated genetic determinants. No single study is likely to have enough cases of these cancer subtypes to perform a GWAS. By pooling cases across the BPC3 studies, the investigators can achieve adequate power to discover genetic variation that gives rise to these important clinical subtypes. For more information, please visit: https://epi.grants.cancer.gov/bpc3/abstract2.htmlRelated Documents:
Related Publications:
Association of breast cancer risk loci with breast cancer survival. (2015)
Genome-wide association study of prostate cancer-specific survival. (2015)
Genetic risk variants associated with in situ breast cancer. (2015)
A genome-wide pleiotropy scan for prostate cancer risk. (2015)
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. (2013)
Genome-wide association study identifies new prostate cancer susceptibility loci. (2011)
Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. (2010)
Performance of common genetic variants in breast-cancer risk models. (2010)
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. (2009)
Complex diseases, complex genes: keeping pathways on the right track. (2009)
Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. (2008)
Multiple loci identified in a genome-wide association study of prostate cancer. (2008)
Haplotypes of the estrogen receptor beta gene and breast cancer risk. (2008)
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. (2007)
A common 8q24 variant in prostate and breast cancer from a large nested case-control study. (2007)
Exploiting gene-environment interaction to detect genetic associations. (2007)
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. (2005)
Genetic variation in the HSD17B1 gene and risk of prostate cancer. (2005)
Class III Obesity and Mortality
Investigator(s):
Cari Kitahara (kitaharac@mail.nih.gov), Patricia Hartge (hartgep@mail.nih.gov), Amy Berrington de Gonzalez (berringtona@mail.nih.gov), and othersYear Initiated:
2014Project Background:
This pooled analysis of 20 prospective cohort studies evaluated total and cause-specific mortality rates for adults with BMI values in the class III obesity range (BMI 40-59) compared with those classified as normal-weight (BMI 18.5-24.9). Study participants included 9,564 adults in the class III obesity group and 304,011 adults in the normal-weight group, all of whom were never smokers and without a history of heart disease, cancer, stroke, or emphysema at study entry. Results were published in 2014.Related Publications:
Cohort Consortium Tissue Project Group
Investigator(s):
Mia Gaudet (mia.gaudet@cancer.org), Lorelie Mucci (lmucci@hsph.harvard.edu), and Danielle Carrick(Danielle.Carrick@nih.gov)Year Initiated:
2014Project Background:
The Cohort Consortium Tissue Working Group was formed in the summer of 2014 to create a community of investigators interested in integrating tissue biomarkers into epidemiological studies. The goals of the working group are: 1. Share lessons learned regarding the acquisition of tumor tissue within cohort studies, 2. Allow other cohorts to learn from experienced cohorts in acquisition of tissue, 3. Develop best practices and technical guidance regarding tissue for cohort studies, 4. Discuss the application of technologies and assays – mRNA profiling, methylation, microRNA, immunohistochemistry, etc – and its use in the archival materials, and 5. Provide a forum for future collaborative work. Webinars are scheduled approximately every 3 months. Please contact Danielle Carrick if you would like to be added to the working group.Related Documents:
Cohort-based GWAS of Glioma (GliomaScan)
Investigator(s):
Martha Linet (linetm@mail.nih.gov), Preetha Rajaraman (rajarama@mail.nih.gov) and Beatrice Melin (beatrice.melin@onkologi.umu.se)Year Initiated:
2008Project Background:
GliomaScan, begun in 2008, investigates the etiology, prevention, and treatment of brain tumors by conducting a GWAS study of glioma with a large number of cohort-derived samples. Follow-up analyses are examining genetic pathways, gene-gene, and gene-environment interactions. The study has found evidence of strong replication for three previously reported associations; larger studies focusing on novel approaches as well as specific tumor subtypes or subgroups will be required to identify additional common susceptibility loci for glioma risk.Related Publications:
Genome-wide association study of glioma and meta-analysis. (2012)
Association between adult height, genetic susceptibility and risk of glioma. (2012)
DNA Methylation Biomarkers of Primary Liver Cancer Risk
Primary Investigator:
Barbara StefanskaProject Details:
View more information here.Related Publications:
Nutriepigenomics: the role of nutrition in epigenetic control of human diseases. (2015)
Diet/Activity Assessment Methods Project
Investigator(s):
Yikyung Park (parky@wudosis.wustl.edu) and Amy Subar (subara@mail.nih.gov)Year Initiated:
2008Project Background:
The Diet/Activity Assessment Methods Project, initiated in 2008, evaluates the measurement error structure of several self-reported, Internet-based, diet and physical activity assessment tools and questionnaires (e.g., food frequency and physical activity) and compares them against reference biomarkers and activity monitors among participants in the NIH-AARP Diet and Health Study, Harvard's Nurses' Health Study, and Health Professionals Follow-up Study.Gastric and Esophageal Squamous Cell Carcinomas GWAS
Investigator(s):
Christian Abnet (abnetc@mail.nih.gov), Alicja Wolk (Alicja.Wolk@ki.se), and othersYear Initiated:
2008Project Background:
This study, initiated in 2008, is conducting a GWAS in two anatomically different upper gastrointestinal cancer sites in two populations with distinctly different disease rates and genetic profiles. One population has very high rates of both esophageal squamous cell carcinoma (ESCC) and gastric cancer (GC) and consists of participants from East Asian countries. The other population has low rates of ESCC and GC and includes participants from the Americas, Europe, Australia, the Middle East, and others.Related Publications:
Genome-Wide Association Study (GWAS) of Renal Cell Carcinoma (RCC)
Primary Investigator:
Mark PurdueProject Details:
View more information here.Related Publications:
Sex specific associations in genome wide association analysis of renal cell carcinoma. (2019)
Genome-wide association study identifies multiple risk loci for renal cell carcinoma. (2017)
Genome-Wide Association Study of Endometrial Cancer
Investigator(s):
Immaculata De Vivo (devivo@channing.harvard.edu) and othersYear Initiated:
2008Project Background:
Begun in 2008, this project is identifying the genes involved in endometrial cancer to help identify novel targets for endometrial cancer risk prediction, prevention, and treatment. The researchers are genotyping more than 2,600 Type I endometrial cancer cases of European descent and an equal number of controls. The effect of the SNPs that indicate genome-wide significance will be characterized in terms of body mass index, exogenous hormone use, and other established endometrial cancer risk factors. This project has been completed and a manuscript is currently under review.Related Publications:
Symposium on advances in endometrial cancer epidemiology and biology. (2015)
Body Mass Index Genetic Risk Score and Endometrial Cancer Risk. (2015)
Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia. (2014)
Genome-wide association study of endometrial cancer in E2C2. (2014)
Exome-wide association study of endometrial cancer in a multiethnic population. (2014)
Type I and II endometrial cancers: have they different risk factors? (2013)
Genomic Determinants of Serum Vitamin D
Investigator(s):
Demetrius Albanes (albanesd@mail.nih.gov)Year Initiated:
2008Project Background:
Prostate cancer is the most common malignancy in men in most developed populations, and few modifiable etiological factors have been established. Substantial recent interest in the potential health benefits of several micronutrients and vitamin supplements, including 25-hydroxy-vitamin D (25(OH)D), tocopherols (vitamin E), and retinol (vitamin A), has raised attention with respect to available human evidence for their relationships to cancer, including prostate cancer. With respect to vitamin D, for example, the Cohort Consortium Vitamin D Pooling Project (VDPP) provided no evidence to support a beneficial association with rarer cancers, but did suggest increased pancreatic cancer risk for persons with the highest 25(OH)D concentrations. Studies of breast and colorectal cancer are ongoing, including within the Cohort Consortium through a recently awarded NCI grant. With respect to prostate cancer, a recent literature review-based meta-analysis of nested case-control studies of 25(OH)D concluded there was no beneficial association for higher vitamin D status, and that a weak causal relation was possible. Findings for aggressive cancers have been limited and less conclusive. By contrast, most basic research supports a beneficial role for vitamin D compounds in prostate cell proliferation and differentiation, prostate cancer cell growth and invasion, and tumorigenesis, and ecologic data suggest correlations between prostate (and other organ site) cancer rates and latitude. Given the clinical significance of prostate cancer, a more definitive understanding is needed of the potential impact vitamin D status may have on its occurrence and outcome. Vitamin E and the tocopherols have been extensively studied and shown potential promise with respect to prostate cancer prevention, yet the results from controlled trials such as the ATBC Study, SELECT, and PHS-II, as well as nested observational serologic studies, raise the issue of a preventive influence being confined to cigarette smokers or during later stages of prostate tumorigenesis. The latter issues remain unresolved at this time. With respect to vitamin A (retinol), some recent analyses also suggest a positive association between serologic status and prostate cancer. To this end, a pooled analysis of nested case-control serologic study data of prostate cancer within the Cohort Consortium is proposed in order to more definitively examine and establish any role for vitamins D, E, and A in its etiology. The association in aggressive and non-aggressive disease will be analyzed separately, and effect modification by several factors that might impact the influence of vitamin D (including physical activity, vitamin D intake, BMI, and time from blood collection to diagnosis) will be tested. Analysis of plasma/serum tocopherols (notably, alpha- and gamma-tocopherol that have been most commonly measured in previous studies) will focus particularly on effect modification by smoking status, in addition to disease aggressiveness and vitamin E supplement usage. Plasma/serum retinol status will also be examined for main effect and interaction with smoking status, and exploratory interactions among the three vitamins will be examined.Related Publications:
Genome-wide association study of circulating vitamin D levels. (2010)
Head and Neck Cancer Risk Factors and Risk Prediction Model Validation
Health Effects of Cigar, Cigarillo, Pipe, and Hookah Smoking
Leisure Time Physical Activity, Body Mass Index, and Risk of Death
Investigator(s):
Steven C. Moore (moorest@mail.nih.gov), Alpa Patel (alpa.patel@cancer.org), and othersYear Initiated:
2011Project Background:
Begun in 2011, the goal of this study is to identify risk of death and years of life lost or gained according to physical activity and BMI levels. This study has been completed and was published in 2012.Related Publications:
Longitudinal Metabolomics Study on Pancreatic Cancer
Lung Cancer Calcium Intake Pooling Project
Primary Investigator:
Xiao-Ou ShuProject Details:
View more information here.Related Publications:
Overall and Central Obesity and Risk of Lung Cancer: A Pooled Analysis. (2018)
Dietary Fat Intake and Lung Cancer Risk: A Pooled Analysis. (2017)
Male Breast Cancer Pooling Project
Investigator(s):
Susan Gapstur (susan.gapstur@cancer.org), Michael Cook (cookmich@mail.nih.gov) and othersYear Initiated:
2008Project Background:
The Male Breast Cancer Pooling Project, begun in 2008, is evaluating data from case-control studies to better understand causes of this rare cancer. Hormonal factors and multiple exposures considered include BMI, physical activity, diet, and family history of breast cancer. Other exposures studied include alcohol consumption, liver and thyroid diseases, infertility history, and occupational exposures. Future studies may involve genetic assays and more detailed pathologic and molecular characterization of the tumors.Related Publications:
Physical Activity and Risk of Male Breast Cancer. (2015)
Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk. (2015)
Menarche and the Risks of Incident Cancers and Mortality by Cause
Primary Investigator:
Barbara FuhrmanProject Details:
View more information here.Related Publications:
Obesity and Rare Cancers
Investigator(s):
Cari Kitahara (kitaharac@mail.nih.gov), Amy Berrington de Gonzalez (berringtona@mail.nih.gov), Peter Campbell (campbell@cancer.org), Mia Gaudet (mia.gaudet@cancer.org), Mark Purdue (purduem@mail.nih.gov), and othersYear Initiated:
2011Project Background:
This project, including 22 prospective studies, will evaluate the relationship between anthropometric measures (e.g., height, baseline BMI, young-adult BMI, BMI change, waist and hip circumference) and the risk of four relatively uncommon malignancies: cancers of the thyroid, gallbladder, head/neck, and kidney. Analyses are currently underway.Related Publications:
Anthropometry and head and neck cancer:a pooled analysis of cohort data. (2015)
One-Carbon Metabolism Biomarkers and Risk of Colorectal Cancer: A Pooled Analysis of Cohorts
Investigator(s):
Paolo Vineis (p.vineis@imperial.ac.uk) and Su-Chun Chuang (s-c.chuang@imperial.ac.uk)Year Initiated:
2011Project Background:
This project began in 2011 to characterize folate, particularly unmetabolized folic acid, and its association with colorectal cancer. The study will explore folate status in different populations, the dose-response relationship between plasma folate and colorectal cancer and assess the effects by demographic, lifestyle, and genetic factors. By pooling data from several NCI cohorts, the project expects to improve comparability among the blood measurements in different cohorts and provide scientific evidence to inform policies on folic acid fortification.Related Publications:
One-Carbon Metabolism Pathway in Relation to the Development of Hepatocellular Carcinoma
Investigator(s):
Jian-Min Yuan (yuanj@upmc.edu) and Lesley Butler (butlerl3@upmc.edu)Year Initiated:
2007Project Background:
This study, begun in 2007, assesses the association between concentrations of one-carbon metabolites in pre-diagnostic blood and the risk of developing hepatocellular carcinoma. The study also is evaluating the modifying effect of genetic polymorphisms in the genes that are involved in one-carbon metabolites and risk of hepatocellular carcinoma. Laboratory measurements of serum one-carbon metabolism biomarkers, with statistical analyses, have been completed on all hepatocellular carcinoma cases and controls of the Shanghai Cohort Study.Related Publications:
Prediagnostic levels of serum one-carbon metabolites and risk of hepatocellular carcinoma. (2013)
Parallel and Pooled Analyses of the Current Risks from Smoking
Investigator(s):
Michael Thun (Michael.Thun@cancer.org) and othersYear Initiated:
2010Project Background:
With the maturation of the tobacco epidemic, the relative risk (RR) estimates associated with current and former smoking continue to change in the U.S., especially among women who began smoking in adolescence, and among former smokers who have abstained for many years. These changes have implications for both estimates of the disease burden attributable to smoking and for our understanding of the etiologic contribution of current and historical smoking patterns to various disease endpoints. Currently, the statistical program used by the CDC to estimate the number of deaths attributable to smoking in the U.S. [called “Smoking Attributable Mortality, Morbidity, and Economic Costs (SAMMEC)] is based on RR estimates for 18 chronic diseases derived from the first six years of follow-up (1982-88) of the American Cancer Society’s Cancer Prevention Study II (CPS-II). Although the CPS-II mortality cohort continues to be followed, the information on smoking status has not been updated since baseline, and analyses based on the early follow-up do not reflect likely changes in risk associated with continued smoking over the last 25 years. Furthermore, the estimates consider only mortality, not incidence, and do not take into account possible variation across racial/ethnic or socioeconomic subgroups. The latter may be most relevant, since smoking has become uncommon in higher socioeconomic groups. Ideally, the CDC Office of Smoking and Health would like to update the RR estimates for all 18 smoking related diseases considered in SAMMEC, which include ten sites or categories of cancer. The current proposal is limited to the five most common smoking-related conditions (lung cancer, ischemic heart disease, other heart disease, stroke, and COPD) that comprise the largest fraction of smoking-attributable deaths. The extent to which this collaboration will present pooled data on other smoking-related cancers must be negotiated among the participating cohorts.Related Documents:
Pooled Analysis of Active Smoking and Breast Cancer Risk
Investigator(s):
Mia M. Gaudet (mia.gaudet@cancer.org)Year Initiated:
2011Project Background:
The Pooled Analysis of Active Smoking and Breast Cancer Risk began in 2012 to address remaining inconsistencies in key methodological issues in individual studies of the relationship between active cigarette smoking and breast cancer, by analyzing pooled data from prospective cohort studies. The factors studied will include smoking duration, alcohol consumption, mammographic screening, age at menopause, BMI, socioeconomic status, reproductive patterns, and use of postmenopausal hormones, and family history of breast cancer.Related Documents:
Related Publications:
Pooled Analysis of Circulating Carotenoids and Breast Cancer Risk
Primary Investigator:
Heather EliassenProject Details:
View more information here.Related Publications:
Pooled Analysis of Multiple Myeloma Mortality in Relation to Anthropometric Characteristics
Investigator(s):
Lauren Teras (lauren.teras@cancer.org), Mark Purdue (purduem@mail.nih.gov), and Cari Kitahara (meinholdc@mail.nih.gov)Year Initiated:
2014Project Background:
This study leveraged the collaboration network of the Multiple Myeloma Cohort Consortium (MMCC) and harmonized data resources of the BMI All-Cause Mortality Pooling Project to examine association of anthropometric measures with multiple myeloma mortality. A collaborative manuscript on anthropometric measures and mortality from multiple myeloma was published in 2014.Related Publications:
Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. (2014)
Pooled Analysis of Time Since Birth and Breast Cancer Subtype
Investigator(s):
Hazel B. Nichols (hazel.nichols@unc.edu)Year Initiated:
2013Project Background:
This project, begun in 2013, pools data from prospective studies to evaluate time since birth and breast cancer risk according to tumor subtypes and pregnancy characteristics, including age and breastfeeding history. The study evaluates whether short-term increases in breast cancer risk after pregnancy are influenced by post-partum behaviors. (This study is conducted jointly with the Pooled Analysis of Risk Factors for Premenopausal Breast Cancer.)Prediagnositic androgens and IGF-I and risk of ovarian cancer
Primary Investigator:
Annekatrin LukanovaProject Details:
View more information here.Related Publications:
Risk factors for acute myeloid leukemia and myelodysplastic syndromes
Vitamin D Pooling Project of Rarer Cancers
Investigator(s):
Kathy Helzlsouer, Stephanie Weinstein (weinstes@mail.nih.gov), Nonye Harvey (harveyn@mail.nih.gov), and othersYear Initiated:
2007Project Background:
This project, initiated in 2007, is a nested case-control study that analyzed the association between 25(OH)D (serum vitamin D concentrations) and the development of seven rarer cancers: endometrial, esophageal, stomach, ovarian, pancreatic, and kidney cancers, and non-Hodgkin lymphoma (NHL). The study involved 10 cohorts, and participants' vitamin D levels were measured in serum collected before the development of cancer. Study findings do not support the hypothesis that circulating 25(OH) D concentrations are associated with a reduced risk of developing any of these seven rarer cancers. The results were published in 2010. For more information, please visit: https://epi.grants.cancer.gov/vitamind/Related Publications:
Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. (2010)